Skip to the content
Please enable JavaScript in your browser to complete this form.
Post meeting evaluation
Location:
*
[Please select]
Hong Kong
Macau
Mainland China
Others
Others:
*
Title:
*
[Please select]
Dr
Professor
Mr
Ms
First Name:
*
Last Name:
*
Institute:
*
Email Address:
*
MCHK Registration Number (Mandatory for obtaining MCHK CME):
*
CME Accreditation:
*
[Please select]
Hong Kong College of Psychiatrists (Fellow)
Hong Kong College of Psychiatrists (Trainee)
Hong Kong College of Physicians
Medical Council of Hong Kong
Not Applicable
1. What is your prescribing experience with lemborexant?
*
[Please select]
A. If you have prescribed lemborexant before, would you now consider prescribing it to a wider variety of insomnia patients?
B. If you haven’t prescribed lemborexant before, do you now feel confident in prescribing it in the future?
If you have prescribed lemborexant before, would you now consider prescribing it to a wider variety of insomnia patients?
*
Yes
No
If yes, please specify which types of patients. Tick all that apply.
*
Newly diagnosed patients
Patients using/tried Z-drugs
Patients using/tried BDZ
Patients using/tried Z-drugs and BDZ
Elderly patients
Patients with psychiatric comorbidities
Patients with medical comorbidities
If no, why not?
*
If you haven’t prescribed lemborexant before, do you now feel confident in prescribing it in the future?
*
Yes
No
If yes, please specify which types of patients. Tick all that apply.
*
Newly diagnosed patients
Patients using/tried Z-drugs
Patients using/tried BDZ
Patients using/tried Z-drugs and BDZ
Elderly patients
Patients with psychiatric comorbidities
Patients with medical comorbidities
If no, why not?
*
2. Were the Asian sub-group analysis and local case studies relevant to your clinical management of insomnia patients?
*
Yes
No
3. How has your confidence in switching from existing hypnotics to lemborexant improved? Rating from 1-4.
*
1 – Not improved
2 – Somewhat improved
3 – Improved
4 – Significantly/greatly improved
4. What additional information would you like to have about DORAs/lemborexant? (Tick all that apply)
*
Use of lemborexant in patients with medical comorbidities
Use of lemborexant in patients with psychiatric comorbidities
Use of lemborexant in the elderly population
Role of orexins in sleep disorders
Sleep architecture
Others
Others (please specify)
*
5. What topics would you like to learn more about at future meetings?
Submit